Your browser is no longer supported. Please, upgrade your browser.
Plus Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.53 Insider Own0.50% Shs Outstand15.36M Perf Week-5.90%
Market Cap13.75M Forward P/E- EPS next Y-1.06 Insider Trans65.58% Shs Float15.29M Perf Month-16.82%
Income-12.80M PEG- EPS next Q-0.27 Inst Own8.50% Short Float0.24% Perf Quarter-46.15%
Sales0.00M P/S- EPS this Y32.90% Inst Trans- Short Ratio0.01 Perf Half Y-56.47%
Book/sh1.11 P/B0.84 EPS next Y-3.00% ROA-67.50% Target Price6.67 Perf Year-61.66%
Cash/sh1.44 P/C0.65 EPS next 5Y- ROE-130.80% 52W Range0.91 - 5.42 Perf YTD-11.28%
Dividend- P/FCF- EPS past 5Y- ROI-103.10% 52W High-82.81% Beta0.31
Dividend %- Quick Ratio- Sales past 5Y-51.80% Gross Margin- 52W Low2.37% ATR0.13
Employees12 Current Ratio2.30 Sales Q/Q- Oper. Margin- RSI (14)34.41 Volatility8.41% 13.32%
OptionableNo Debt/Eq0.46 EPS Q/Q28.50% Profit Margin- Rel Volume0.14 Prev Close0.99
ShortableYes LT Debt/Eq0.00 EarningsOct 21 AMC Payout- Avg Volume3.27M Price0.93
Recom- SMA20-14.99% SMA50-27.76% SMA200-51.63% Volume461,079 Change-5.47%
Jan-25-21Initiated Ladenburg Thalmann Buy $8
Oct-16-20Initiated Maxim Group Buy $6
Jan-14-22 07:41AM  
Jan-07-22 07:00AM  
Jan-06-22 07:00AM  
Jan-04-22 07:53AM  
Dec-02-21 07:30AM  
Nov-22-21 07:31AM  
Nov-18-21 02:18PM  
Nov-12-21 07:30AM  
Nov-09-21 07:00AM  
Nov-03-21 07:00AM  
Oct-29-21 10:04AM  
Oct-27-21 02:00PM  
Oct-21-21 04:05PM  
Oct-19-21 07:30AM  
Oct-14-21 07:30AM  
Sep-30-21 08:00AM  
Sep-27-21 07:30AM  
Sep-23-21 07:30AM  
Sep-13-21 07:00AM  
Sep-08-21 07:00AM  
Sep-02-21 07:00AM  
Aug-23-21 06:25AM  
Aug-21-21 09:24AM  
Aug-19-21 08:13AM  
Aug-13-21 07:51AM  
Aug-11-21 10:12AM  
Aug-05-21 07:30AM  
Jul-27-21 07:00AM  
Jul-22-21 04:05PM  
Jul-15-21 07:30AM  
Jun-16-21 07:30AM  
Jun-10-21 07:30AM  
Jun-09-21 04:15PM  
May-24-21 06:46AM  
May-04-21 07:30AM  
Apr-22-21 04:05PM  
Apr-08-21 07:30AM  
Mar-23-21 07:30AM  
Mar-18-21 08:30AM  
Mar-05-21 11:51AM  
Mar-04-21 11:04AM  
Mar-03-21 07:30AM  
Mar-02-21 07:30AM  
Mar-01-21 07:30AM  
Feb-22-21 04:05PM  
Feb-11-21 04:15PM  
Jan-11-21 10:11AM  
Jan-05-21 04:15PM  
Dec-15-20 07:30AM  
Dec-08-20 07:30AM  
Dec-01-20 07:30AM  
Nov-19-20 08:00AM  
Nov-16-20 08:00AM  
Nov-13-20 07:30AM  
Nov-12-20 07:25AM  
Nov-05-20 07:00AM  
Oct-29-20 07:00AM  
Oct-22-20 04:05PM  
Oct-15-20 07:00AM  
Oct-14-20 04:15PM  
Oct-02-20 07:00AM  
Oct-01-20 07:00AM  
Sep-15-20 07:00AM  
Sep-09-20 07:00PM  
Sep-03-20 07:00AM  
Sep-01-20 07:00AM  
Aug-28-20 07:00AM  
Aug-25-20 10:31AM  
Aug-10-20 07:43AM  
Aug-03-20 07:00AM  
Jul-28-20 07:00AM  
Jul-23-20 05:00PM  
Jul-06-20 08:01AM  
May-14-20 04:27PM  
May-12-20 08:57AM  
May-11-20 06:00AM  
May-07-20 04:15PM  
Apr-16-20 04:15PM  
Apr-06-20 07:00AM  
Apr-01-20 07:00AM  
Mar-30-20 04:05PM  
Mar-25-20 05:53PM  
Mar-12-20 07:15AM  
Feb-06-20 05:00PM  
Jan-06-20 07:15AM  
Jan-02-20 04:15PM  
Dec-09-19 07:00AM  
Nov-25-19 07:00AM  
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian cancer. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sims Andrew John Hugh MacIntyrChief Financial OfficerNov 02Buy1.861,0001,8647,230Nov 04 06:15 AM
Petersen GregDirectorOct 27Buy1.7212,50021,50032,500Oct 28 06:15 AM
HEDRICK MARC HChief Executive OfficerOct 26Buy1.662,5004,15021,080Oct 27 06:15 AM
Sims Andrew John Hugh MacIntyrChief Financial OfficerOct 26Buy1.672,0003,3396,230Oct 27 06:15 AM
Lenk Robert PDirectorSep 13Buy1.867,00013,01110,000Sep 15 07:30 AM
Sims Andrew John Hugh MacIntyrChief Financial OfficerJul 28Buy1.912,2444,2864,230Jul 29 06:35 PM
Sims Andrew John Hugh MacIntyrChief Financial OfficerJul 27Buy2.051,9864,0711,986Jul 29 06:35 PM
HEDRICK MARC HChief Executive OfficerApr 30Buy2.282,1834,97018,580May 03 06:15 AM
HEDRICK MARC HChief Executive OfficerMar 04Buy2.502,5006,25016,397Mar 05 06:15 AM
Clowes HowardDirectorMar 03Buy2.423,0007,2603,000Mar 04 06:15 AM